The Effects of Seromegatives on Rheumatoid Factors

OP0130 is the long-awaited epipar study preclinical RA cohort 206 patients they had to be seropositive going in and have our througher. Abattasum significantly fewer patients on abattasum develop rheumatoid arthritis 6% versus 29% on placebo. A late-breaking abstract looked at a new dual inhibitor of Jack 1 and tick 2 it's called TLL 018 head-to-head against Topocet in a 5 milligrams BID both drugs are given BID in a phase 2A trial again this looked really good with surprising results almost too good to be true week 12 ACR 50 responders with 72% for